Holen Sie sich die Stockscreener-App
5.22
1.95%
0.10
Handel nachbörslich:
5.20
-0.02
-0.38%
Schlusskurs vom Vortag:
$5.12
Offen:
$5.12
24-Stunden-Volumen:
526.08K
Relative Volume:
0.79
Marktkapitalisierung:
$672.39M
Einnahmen:
$193.01M
Nettoeinkommen (Verlust:
$-12.15M
KGV:
-58.00
EPS:
-0.09
Netto-Cashflow:
$454.00K
1W Leistung:
-0.19%
1M Leistung:
-9.06%
6M Leistung:
-7.61%
1J Leistung:
-40.14%
1-Tages-Spanne:
$5.12
$5.28
1-Wochen-Bereich:
$5.11
$5.42
52-Wochen-Spanne:
$4.66
$9.3283
Cytek Biosciences Inc Stock (CTKB) Company Profile
Firmenname
Cytek Biosciences Inc
Sektor
Branche
Telefon
(877) 922-9835
Adresse
47215 LAKEVIEW BOULEVARD, FREMONT
Vergleichen Sie CTKB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
5.22 | 672.39M | 193.01M | -12.15M | 454.00K | -0.09 |
|
ABT
Abbott Laboratories
|
134.95 | 234.06B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.39 | 154.06B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
387.92 | 148.02B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.17 | 115.71B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.76 | 42.91B | 5.72B | 4.17B | 490.10M | 6.97 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-31 | Herabstufung | Goldman | Buy → Sell |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-07-19 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
Cytek Biosciences Inc Aktie (CTKB) Neueste Nachrichten
(CTKB) Proactive Strategies - Stock Traders Daily
Cytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest Update - MarketBeat
Cytek Biosciences (CTKB) Projected to Post Quarterly Earnings on Thursday - Defense World
Cytek Biosciences (NASDAQ:CTKB) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Prenetics Global (NASDAQ:PRE) and Cytek Biosciences (NASDAQ:CTKB) Head to Head Analysis - Defense World
Cytek Biosciences to Announce Q4 and Full Year 2024 Financial Results on February 27, 2025 - Nasdaq
Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - GlobeNewswire
Cytek Biosciences Earnings Alert: Key Q4 and Full Year 2024 Results Coming February 27 - StockTitan
Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Cytek Biosciences (NASDAQ:CTKB) Sees Unusually-High Trading Volume – Here’s What Happened - Defense World
Keeping an Eye on Cytek BioSciences Inc (CTKB) After Insider Trading Activity - Knox Daily
Cytek Biosciences (NASDAQ:CTKB) Trading Down 4%Should You Sell? - MarketBeat
Cytek Biosciences (NASDAQ:CTKB) Shares Up 5%What's Next? - MarketBeat
Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
Strategic Investor Access: Cytek Sets Ambitious 4-Conference Roadshow for Early 2025 - StockTitan
Pacer Advisors Inc. Buys Shares of 30,155 Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (NASDAQ:CTKB) Trading Down 4% – Should You Sell? - Armenian Reporter
Market Insights: Cytek BioSciences Inc (CTKB)’s Notable Gain of 4.66, Closing at 5.39 - The Dwinnex
Cytek Biosciences (NASDAQ:CTKB) Stock Rating Lowered by The Goldman Sachs Group - MarketBeat
Cytek Biosciences price target raised to $5.25 from $4.50 at Goldman Sachs - MSN
Cytek Biosciences (NASDAQ:CTKB) Cut to Sell at The Goldman Sachs Group - Defense World
Cytek Biosciences (NASDAQ:CTKB) Shares Down 5.5%What's Next? - MarketBeat
Cytek Biosciences (NASDAQ:CTKB) Shares Gap DownWhat's Next? - MarketBeat
(CTKB) Trading Report - news.stocktradersdaily.com
Cytek cut from buy to sell by Goldman Sachs (CTKB:NASDAQ) - Seeking Alpha
Goldman Sachs cuts Cytek Biosciences stock rating to sell - MSN
Goldman Sachs Downgrades Cytek Biosciences to Sell From Buy, Adjusts Price Target to $4.50 From $7 - Marketscreener.com
Goldman Sachs cuts Cytek Biosciences stock rating to sell By Investing.com - Investing.com UK
Cytek Biosciences, Inc. (NASDAQ:CTKB) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance
Institutional investors may adopt severe steps after Cytek Biosciences, Inc.'s (NASDAQ:CTKB) latest 24% drop adds to a year losses - Simply Wall St
JPMorgan Chase & Co. Lowers Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (NASDAQ:CTKB) Preliminary Full Year 2024 Revenue Results AnnouncedOn January 15, 2025, Cytek Biosciences, Inc. released its preliminary unaudited revenue for the fourth quarter and full year that concluded on December 31, 2024. T - Defense World
Cytek Biosciences expects FY24 revenue to be between $200M and $201M - MSN
Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results - GlobeNewswire
Cytek Biosciences, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024 - Marketscreener.com
Cytek Biosciences shares take a hit after Q4 sales miss estimates By Investing.com - Investing.com South Africa
Cytek Biosciences shares take a hit after Q4 sales miss estimates - Investing.com Canada
Cytek Biosciences reports 4% annual revenue growth By Investing.com - Investing.com Australia
Cytek Biosciences Shares Fall On Low Preliminary 4Q Revenue - MarketWatch
Cytek Biosciences reports 4% annual revenue growth - Investing.com
Cytek Biosciences Projects 4% Revenue Growth to $201M for 2024, Mixed Q4 Performance - StockTitan
GAMMA Investing LLC Acquires 3,635 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Barclays PLC Increases Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - MarketBeat
Finanzdaten der Cytek Biosciences Inc-Aktie (CTKB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):